HLB 오너2세 진인혜, 신약 개발 ‘중책’…항암제 다각화 승부수

HLB's expanded oncology pipeline—combining internally developed drugs like Ribociclib with next-generation candidates like CAR-T therapies—represents a critical turning point for Korean biotech firms seeking to achieve FDA approvals through in-house R&D. With multiple clinical milestones expected by September 2026, HLB's success could establish a blueprint for succession planning tied to business results, demonstrating that second-generation leadership can emerge through demonstrated competence rather than inheritance alone.